Skip to main content
INVA logo

INVA · Innoviva, Inc.

Track INVA — free
$18.41 +0.01 (+0.05%) At close · Nov 19
Market Cap
$1.31B
Shares
71.08M
Volume · Nov 19 839.65K Avg daily vol (3M) 856.57K

Price & Indicators

 

Key stats

Close
$18.41
Open
$18.31
Day range
$18.19–18.56
52-week closing range
$18.30–24.24
Average volume, 30 days
831K
Short interest
7.5M · 10.5% of shares · 12.9 days
Short volume, last session
52%
Last earnings
May 8, 2024
Latest filing
10-Q · Nov 4
Price history
Jan 2020 to Nov 2026

Latest documents

2026
Nov 4
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Product growth supports operations amid investment losses

Innoviva reported for the third quarter of 2026 revenue of $106.1 million, net product sales of $49.4 million and income from operations of $42.2 million, but a net loss of $73.9 million driven by investment fair-value declines; cash and cash equivalents totaled $581.4 million.

Revenue $106.12M ▼ 1.6% Net loss $73.89M Diluted EPS -$1.03
Read from the MD&A section
7 source passages
Innoviva, Inc. Third Quarter 2026 and Recent Highlights: Total revenue: $106.1 million Net product sales: $49.4 million Income from operations: $42.2 million Net income (loss): net loss of $73.9 million Cash and cash equivalents: totaled $581.4 million. Open the document at this passage
Nov 4
Current report 8-K
U.S. product sales rose 45%; net loss reached $73.9 million

Innoviva reported third-quarter total revenue of $106.1 million, including $43.3 million of U.S. net product sales, up 45% year over year, but posted a $73.9 million net loss for the quarter ended September 30, 2026.

Financial results
4 source passages
Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (IST), and a portfolio of strategic investments in healthcare assets, today reported financial results for the third quarter ended September 30, 2026, and highlighted select corporate progress and achievements. Total revenue: $106.1 million, decreased modestly by 1.6% year over year compared to $107.8 million for the third quarter of 2025, as growth in U.S. net product sales was partially offset with lower royalty revenue and fluctuations in the timing of inventory sales to ex-U.S. partners. Net product sales: $49.4 million, comprising $43.3 million in U.S. net product sales and $6.1 million in ex-U.S. sales. U.S. net product sales increased 45% year-over-year, compared to $29.9 million in the same quarter of 2025. Net income: net loss of $73.9 million, or $1.03 basic loss per share, driven primarily by a decrease in fair value of equity and long-term investments. Open the document at this passage
Aug 5
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $119.59M ▲ 19.3% Net loss $83.42M Diluted EPS -$1.14
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$438.32M
Trailing 12 months
Net income (TTM)
$193.44M
Trailing 12 months
Revenue growth YoY
-1.6%
Year over year
Operating margin
38.8%
Trailing 12 months
P / E (TTM)
8.2
Trailing earnings · reciprocal yield 12.2%
FCF yield
13.9%
TTM · current market cap
Return on invested capital
18.0%
Trailing 12 months
Net cash
$322.57M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
-15.2%
Year over year · fewer shares
Price change (1Y)
-13.4%
Trailing year
Short interest
10.5%
Latest settlement · 12.9 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Bearish Fundamentals Excellent Quant / Vol Moderate
Market backdrop VIX 28.4 · fear Equity put/call 0.72
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −16%
below
Price vs 50-day avg −10%
below
RSI (14) 29
oversold
MACD trend Negative
52-week position 2%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −13%
trailing
6-month return −14%
trailing
YTD return −8%
this year
Relative strength −9%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50d $20 › 200d $22 — 200d above 50d
Institutional flow Distributing
-6% holders QoQ · +37 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
10.54% of shares out · ▲ +3.2% MoM · 12.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
293 holders — mid 3-yr range
Squeeze score 70
elevated · 0–100
Fundamentals
Excellent
Revenue growth +63%
Y/Y
Gross margin 142%
contracting
EPS growth +817%
Y/Y
Free cash flow $195.8M
Valuation P/E 8.2
below peers
Buyback $42.3M
remaining
Balance sheet $293.2M
net cash
Quant / Vol
risk profile
Moderate
Volatility 25%
annualized · 1-yr
Max drawdown −25%
past year
ATR 3.3%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the 8-K filed Nov 4, 2026
U.S. net product sales · 2026 at least $150M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−16% Bearish
Price vs 50-day avg
−10% Bearish
RSI (14)
29 Neutral
MACD trend
Negative Bearish
52-week position
2% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $20 › 200d $22 — 200d above 50d
Institutional flow Distributing
-6% holders QoQ · +37 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
10.54% of shares out · ▲ +3.2% MoM · 12.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
293 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $18 Now $18 · 2% Range high $24
vs 200-day avg -16% vs 50-day avg -10%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
INVA
Innoviva, Inc.
this stock
$1.31B -7.9% +62.6% 8.2 10.5%
VRTX
Vertex Pharmaceuticals Inc
$132.01B +14.8% +46.2% 33.5 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.52B +19.6% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$80.65B +575.9% +4.3% — 8.2%
CSLLY
Csl Ltd
$63.36B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
293
% held
103.0%
Net QoQ
-1.4M sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
336
View
Short & Settlement
Short Interest Rising
Shares short
7.5M
Days to cover
12.9d
Change
+229.5K sh
View
Short Volume
Short vol %
52%
As of
Nov 19, 2026
Short Total
View
Fails to Deliver
FTD shares
1.1K
Value
$23.2K
As of
Oct 26, 2026
View
Off-Exchange
Off-exchange %
36.6%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Congressional Trades Sell
Member
George Whitesides
Amount
$250.0K–$500.0K
Traded
Mar 25, 2025
View
Financials
Financials
Revenue (FY)
$411.3M
EPS diluted
$3.30
View
Buybacks
Authorized
$125.0M
Remaining
$42.3M
Spent Remaining
View
Filings
SEC Filings
Latest
10-Q
Filed
Nov 4, 2026
This year
14

Innoviva reported for the third quarter of 2026 revenue of $106.1 million, net product sales of $49.4 million and income from operations of $42.2 million, but a net loss of $73.9 million driven by investment fair-value declines; cash and cash equivalents totaled $581.4 million.

View
Earnings & Events
Webcasts
Last webcast
Sep 14, 2026
View
Investor Relations
Latest news
Innoviva Reports Third Quarter 20…
Published
Nov 4, 2026
View

Performance

5D 20D 120D MTD YTD
INVA -3.0% -12.6% -14.4% -13.2% -7.9%
SPY -5.5% -6.3% -5.6% -5.3% +5.0%
vs SPY +2.5% -6.3% -8.8% -8.0% -12.9%

Capital returns

Buyback program · as of Sep 30, 2026
Authorized
$125.00M
Spent (derived)
$82.70M
Remaining
$42.30M
Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1080014 CUSIP 45781M101 13F (30d) 299 filings 267 filers Visit website Investor relations